ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares of Stock

Posted by Stanley Muller on Jul 1st, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) CFO Stephen Carey sold 2,850 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $84.12, for a total value of $239,742.00. Following the completion of the sale, the chief financial officer directly owned 177,543 shares in the company, valued at $14,934,917.16. This represents a 1.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $82.78 on Wednesday. ANI Pharmaceuticals, Inc. has a 1 year low of $62.60 and a 1 year high of $99.50. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 20.96 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm has a fifty day moving average of $80.74 and a 200-day moving average of $79.34.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently bought and sold shares of the stock. KBC Group NV acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter valued at $28,000. Hantz Financial Services Inc. increased its position in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares during the period. Kemnay Advisory Services Inc. bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth $48,000. Finally, State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of recent analyst reports. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

Check Out Our Latest Analysis on ANI Pharmaceuticals

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.